Paper Details

  1. Home
  2. Paper Details

Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.

Author: AnthonyMary S, DanyshHeather E, DempseyColleen, FornsJoan, LaytonJ Bradley, McQuayLisa J, TurnerMary Ellen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pimavanserin was associated with lower mortality rates compared to other atypical antipsychotics in patients with Parkinson's disease psychosis.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Pimavanserin is approved in the USA to treat hallucinations and delusions associated with Parkinson's disease psychosis (PDP). OBJECTIVES: We evaluated mortality in patients with PDP after initiation of pimavanserin or comparator atypical antipsychotics, overall, over time, and across...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883317/

データ提供：米国国立医学図書館（NLM）

Mortality in Parkinson's Disease-Related Psychosis Patients Treated with Pimavanserin

This research investigates the mortality rates in patients with Parkinson's disease-related psychosis (PDP) who were treated with pimavanserin compared to those treated with other atypical antipsychotics. The researchers conducted a cohort study using Medicare claims data from 2016 to 2019, comparing the mortality rates of 2892 patients who initiated pimavanserin with 19,083 patients who initiated other atypical antipsychotics.

Pimavanserin and Mortality in PDP Patients

The researchers found that mortality rates were lower among patients treated with pimavanserin compared to those treated with other atypical antipsychotics. This lower mortality risk was observed across various subgroups, including those residing in long-term care or skilled nursing facilities. The findings suggest that pimavanserin may be associated with a reduced risk of mortality in patients with PDP.

A Promising Treatment for Parkinson's Disease-Related Psychosis

This study provides evidence suggesting that pimavanserin may be a safer treatment option for PDP compared to other atypical antipsychotics, potentially leading to improved outcomes for patients. It's like a camel caravan navigating a treacherous desert – a skilled guide chooses the safest and most efficient route to ensure the well-being of the entire caravan. The researchers emphasize the importance of considering pimavanserin as a potential treatment option for patients with PDP.

Dr. Camel's Conclusion

This research examines the potential benefits of pimavanserin for the treatment of Parkinson's disease-related psychosis, highlighting its potential to improve outcomes for patients. It's like a camel caravan navigating a vast desert – a skilled guide knows how to choose the safest and most efficient route to ensure the well-being of the entire caravan. The researchers advocate for considering pimavanserin as a potential treatment option for patients with PDP.

Date :
  1. Date Completed 2023-01-31
  2. Date Revised 2023-03-02
Further Info :

Pubmed ID

36517664

DOI: Digital Object Identifier

PMC9883317

Related Literature

Article Analysis
・Effects of pimavanserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.